We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Read MoreHide Full Article
Key Takeaways
Medical sector earnings have started strong, with all reported companies beating earnings estimates.
ARQT, CATX, NUVB and TNGX are likely to surpass earnings estimates in the second quarter.
Strong early pharma and biotech results set the stage as more companies prepare to report quarterly earnings.
The second-quarter 2026 earnings season is currently in full swing. The scorecard for the Medical sector is pretty good so far. The sector primarily comprises pharma/biotech and medical device companies.
The Earnings Trends report indicates that, as of July 29, 10.2% of the companies in the Medical sector, representing about 32.2% of the sector’s market capitalization, have reported quarterly earnings. While 100% of the companies topped on earnings, 94.7% beat on sales. While earnings increased 18.1% year over year, sales grew 6.8%. Overall, second-quarter earnings are expected to fall 15.2% year over year, while revenues are likely to rise 6.1%.
Zeroing in on Winners
Even though some of the bigwigs from the biotech sector have already announced results, there are many companies that are yet to report. Some of them seem poised to surpass estimates for the quarter. Here, we have highlighted four biotech companies, Arcutis Biotherapeutics (ARQT - Free Report) , Nuvation Bio (NUVB - Free Report) , Perspective Therapeutics, Inc. (CATX - Free Report) and Tango Therapeutics (TNGX - Free Report) — that are expected to deliver a beat in their upcoming quarterly results.
Earnings ESP is our proprietary methodology for determining the stocks with the best chance of delivering an earnings surprise. It shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate.
According to the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. The selection can be made with the help of the Zacks Stock Screener.
Our research shows that the chance of an earnings surprise for stocks with this combination is as high as 70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
4 Biotech Stocks That Match the Criteria
Arcutis Biotherapeutics
Arcutis Biotherapeutics, a commercial-stage medical dermatology, has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Continued robust demand for flagship product, Zoryve, is boosting top-line revenue growth.
ARQT has an Earnings ESP of +52.94% and a Zacks rank 2. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $121.85 million, while the same for earnings is pinned at 9 cents per share.
Arcutis Biotherapeutics, Inc. Price, Consensus and EPS Surprise
ARQT is scheduled to report second-quarter results on Aug. 5.
Nuvation Bio
Nuvation Bio is a global oncology company focused on developing innovative therapies for difficult-to-treat cancers. Its pipeline includes taletrectinib (IBTROZI), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and a novel drug-drug conjugate (DDC) program, all aimed at improving outcomes for patients with cancer.
NUVB has an Earnings ESP of +10.35% and a Zacks Rank of 2. The Zacks Consensus Estimate for revenues is pegged at $27.12 million, while the same for earnings is pinned at a loss of 15 cents per share.
Nuvation Bio Inc. Price, Consensus and EPS Surprise
NUVB is scheduled to report second-quarter results on Aug. 6.
Perspective Therapeutics
Perspective Therapeutics is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The company is advancing a portfolio of clinical-stage programs in the United States, including VMT-α-NET (neuroendocrine tumors), VMT01 (melanoma), and PSV359 (solid tumors).
CATX has an Earnings ESP of +1.89% and a Zacks Rank of 2. The Zacks Consensus Estimate for revenues is pegged at $0.2 million, while the same for earnings is pinned at a loss of 27 cents per share.
Perspective Therapeutics, Inc. Price, Consensus and EPS Surprise
CATX is scheduled to report second-quarter results on Aug. 10.
Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel cancer drug targets and developing next-generation precision medicines. The company is advancing two selective PRMT5 inhibitors targeting MTAP-deleted cancers.
TNGX’s lead candidate, vopimetostat (TNG462), is being evaluated for non-central nervous system (non-CNS) cancers as both a monotherapy and in combination with RAS inhibitors. The company's second candidate, TNG456, is a next-generation, brain-penetrant PRMT5 inhibitor being developed for central nervous system (CNS) cancers, including glioblastoma (GBM).
View the Zacks #1 Rank List
Image: Bigstock
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Key Takeaways
The second-quarter 2026 earnings season is currently in full swing. The scorecard for the Medical sector is pretty good so far. The sector primarily comprises pharma/biotech and medical device companies.
The earnings season for the pharma/biotech sector kicked off last month when pharma bellwether Johnson & Johnson posted better-than-expected results and upped its annual guidance. Swiss pharma giant Novartis also beat on earnings and sales in the second quarter. On the biotech front, Bristol-Myers (BMY) beat earnings and revenue estimates, driven by Growth Portfolio strength and Eliquis demand. Biogen also posted strong results, beating both earnings and sales estimates.
The Earnings Trends report indicates that, as of July 29, 10.2% of the companies in the Medical sector, representing about 32.2% of the sector’s market capitalization, have reported quarterly earnings. While 100% of the companies topped on earnings, 94.7% beat on sales. While earnings increased 18.1% year over year, sales grew 6.8%. Overall, second-quarter earnings are expected to fall 15.2% year over year, while revenues are likely to rise 6.1%.
Zeroing in on Winners
Even though some of the bigwigs from the biotech sector have already announced results, there are many companies that are yet to report. Some of them seem poised to surpass estimates for the quarter. Here, we have highlighted four biotech companies, Arcutis Biotherapeutics (ARQT - Free Report) , Nuvation Bio (NUVB - Free Report) , Perspective Therapeutics, Inc. (CATX - Free Report) and Tango Therapeutics (TNGX - Free Report) — that are expected to deliver a beat in their upcoming quarterly results.
Earnings ESP is our proprietary methodology for determining the stocks with the best chance of delivering an earnings surprise. It shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate.
According to the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. The selection can be made with the help of the Zacks Stock Screener.
Our research shows that the chance of an earnings surprise for stocks with this combination is as high as 70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
4 Biotech Stocks That Match the Criteria
Arcutis Biotherapeutics
Arcutis Biotherapeutics, a commercial-stage medical dermatology, has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Continued robust demand for flagship product, Zoryve, is boosting top-line revenue growth.
ARQT has an Earnings ESP of +52.94% and a Zacks rank 2. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $121.85 million, while the same for earnings is pinned at 9 cents per share.
Arcutis Biotherapeutics, Inc. Price, Consensus and EPS Surprise
Arcutis Biotherapeutics, Inc. price-consensus-eps-surprise-chart | Arcutis Biotherapeutics, Inc. Quote
ARQT is scheduled to report second-quarter results on Aug. 5.
Nuvation Bio
Nuvation Bio is a global oncology company focused on developing innovative therapies for difficult-to-treat cancers. Its pipeline includes taletrectinib (IBTROZI), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and a novel drug-drug conjugate (DDC) program, all aimed at improving outcomes for patients with cancer.
NUVB has an Earnings ESP of +10.35% and a Zacks Rank of 2. The Zacks Consensus Estimate for revenues is pegged at $27.12 million, while the same for earnings is pinned at a loss of 15 cents per share.
Nuvation Bio Inc. Price, Consensus and EPS Surprise
Nuvation Bio Inc. price-consensus-eps-surprise-chart | Nuvation Bio Inc. Quote
NUVB is scheduled to report second-quarter results on Aug. 6.
Perspective Therapeutics
Perspective Therapeutics is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The company is advancing a portfolio of clinical-stage programs in the United States, including VMT-α-NET (neuroendocrine tumors), VMT01 (melanoma), and PSV359 (solid tumors).
CATX has an Earnings ESP of +1.89% and a Zacks Rank of 2. The Zacks Consensus Estimate for revenues is pegged at $0.2 million, while the same for earnings is pinned at a loss of 27 cents per share.
Perspective Therapeutics, Inc. Price, Consensus and EPS Surprise
Perspective Therapeutics, Inc. price-consensus-eps-surprise-chart | Perspective Therapeutics, Inc. Quote
CATX is scheduled to report second-quarter results on Aug. 10.
Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel cancer drug targets and developing next-generation precision medicines. The company is advancing two selective PRMT5 inhibitors targeting MTAP-deleted cancers.
TNGX’s lead candidate, vopimetostat (TNG462), is being evaluated for non-central nervous system (non-CNS) cancers as both a monotherapy and in combination with RAS inhibitors. The company's second candidate, TNG456, is a next-generation, brain-penetrant PRMT5 inhibitor being developed for central nervous system (CNS) cancers, including glioblastoma (GBM).
The company has an Earnings ESP of +1.06% and a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Tango Therapeutics, Inc. Price, Consensus and EPS Surprise
Tango Therapeutics, Inc. price-consensus-eps-surprise-chart | Tango Therapeutics, Inc. Quote
The Zacks Consensus Estimate for second-quarter earnings is pegged at a loss of 31 cents per share.
Tango Therapeutics beat on earnings in two of the trailing four quarters and met in the remaining two, delivering an average surprise of 301.61%.